Company / R&D per Share
Crinetics Pharmaceuticals, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$3.47
FY2025
5-year range
$1.77 / $3.47
FY2021-FY2025
Trend
+34.4%
vs FY2024
Sector context
#59 of 208
Health Care
What the data says
At $3.47, Crinetics Pharmaceuticals, Inc.'s r&d per share ranks #59 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $1.01 in FY2020 to $383.73 in FY2019.
Based on SEC 10-K filings.
3.47 in FY2025 with a 5-year CAGR of +28.1%.
Improved from $2.90 to $3.47 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +12.9%
- 5-Year CAGR
- +28.1%
- 10-Year CAGR
- -
Sector benchmark
#59 of 208 in Health CareTop 28% of 208This company $3.47 Sector average $28.82
▼
-87.9% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 34.4% year-over-year.
- Ranks #59 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2019.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.47 | +34.4% |
| FY2024 | $2.58 | -10.9% |
| FY2023 | $2.90 | +20.1% |
| FY2022 | $2.42 | +36.5% |
| FY2021 | $1.77 | +75.5% |
| FY2020 | $1.01 | -99.7% |
| FY2019 | $383.73 | +11559.3% |
| FY2018 | $3.29 | -51.1% |
| FY2017 | $6.73 | +33.5% |
| FY2016 | $5.04 | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026